AdvaMedDx | GenomeWeb

AdvaMedDx

CMS gave labs an additional year to gear up for the implementation of the Protecting Access to Medicare Act of 2014 and clarified key programmatic definitions.

Multiple legislative proposals before Congress show regulation of lab-developed tests remains divisive within the life sciences community.

Kapa Biosystems said this week that it has added four new managers as part of the company's expansion, which included moving and in

AdvaMedDx announced this week that it has elected John Bishop, CEO of Cepheid, as the new chair of its board of directors. Before joining Cepheid in 2002, he was CEO and president of Vysis.

This article has been updated with information about a Citizen Petition filed against FDA regulation of LDTs by the American Clinical Laboratory Association, and with quotes from Sherri Bale. Originally published June 4.

AdvaMedDx, a division of the Advanced Medical Technology Association, announced the election of several new members to its board of directors.

Originally published Oct. 1.
A new bill strongly supported within the diagnostics industry could put pressure on the Centers for Medicare & Medicaid Services to alter its procedures for setting reimbursement rates for molecular diagnostics.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.